Metformax Sr 1000

Metformin Hydrochloride, the active ingredient in Metformax Sr 1000, is a biguanide presented as a 1000 mg extended‑release tablet for oral use. It is indicated for the management of type 2 diabetes mellitus in adults, helping to lower elevated blood glucose levels by improving the body’s response to insulin.

GNH USA supplies Metformax Sr 1000 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, pharmacies and clinics worldwide, ensuring quality and regulatory compliance for global distribution to meet local health authority standards.

Metformax Sr 1000 (metformin hydrochloride) is used in the management of disorders related to glucose metabolism, primarily type 2 diabetes mellitus. - Type 2 diabetes mellitus: improves glycemic control by reducing hepatic glucose output and enhancing peripheral insulin sensitivity. - Prediabetes (impaired glucose tolerance): may delay progression to overt diabetes by improving insulin sensitivity. - Polycystic ovary syndrome (PCOS): used off‑label to reduce insulin resistance and aid menstrual regularity.

Metformax Sr 1000 may cause a range of adverse reactions, most of which are mild and transient.

Common Side Effects: - Nausea: mild to moderate gastrointestinal upset. - Diarrhea: loose stools, often early in therapy. - Abdominal discomfort: cramping or bloating. - Metallic taste: transient alteration in taste perception. - Loss of appetite: reduced desire to eat. - Flatulence: increased intestinal gas.

Serious or Rare Side Effects: - Lactic acidosis: rare but potentially fatal metabolic acidosis. - Severe skin reactions: such as Stevens‑Johnson syndrome or toxic epidermal necrolysis. - Hepatic dysfunction: elevated liver enzymes or hepatitis. - Vitamin B12 deficiency: long‑term use may reduce absorption. - Pancreatitis: inflammation of the pancreas. - Hypoglycemia: when combined with other glucose‑lowering agents.

Metformax Sr 1000 requires careful patient assessment and monitoring to minimise risks. - Renal function assessment: evaluate eGFR before initiating and periodically during therapy. - Lactic acidosis risk: avoid in patients with significant renal or hepatic impairment. - Alcohol consumption: limit intake as it may increase lactic acidosis risk. - Pregnancy and lactation: use only if benefits outweigh risks; classified as Category B. - Drug interactions: review concomitant medications for potential interactions. - Store at ambient temperature: keep below 25 °C, retain in original packaging, protect from moisture.

Metformax Sr 1000 can interact with several medicines, necessitating vigilance.

Major Interactions (Avoid): - Iodinated contrast agents: may precipitate renal dysfunction and increase lactic acidosis risk. - Cimetidine: can raise metformin plasma concentrations. - Didanosine (NRTI): heightened risk of lactic acidosis. - Alcohol abuse: synergistic effect on lactic acidosis development. - Probenecid: may increase metformin levels by inhibiting renal tubular secretion.

Moderate Interactions (Monitor Closely): - Beta‑blockers: may mask hypoglycemia symptoms. - Thiazide diuretics: can elevate blood glucose levels. - Corticosteroids: may reduce metformin efficacy. - ACE inhibitors/ARBs: monitor renal function and electrolytes. - Sulfonylureas: increased risk of hypoglycemia when combined.